Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638610 | 0.95 | KDM4E (0.50) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL17713226 | 0.95 | KDM4E (0.50) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL27534696 | 0.95 | KDM4E (0.46) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL828480 | 0.89 | GABRA1 (0.48) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL14785529 | 0.88 | MYC (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2280244 | 0.87 | ELANE (0.47) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL25337349 | 0.86 | CA12 (0.48) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL20928681 | 0.86 | RXRA (0.41) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL3982155 | 0.86 | EGFR (0.49) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL1606267 | 0.86 | TSHR (0.42) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567470-B1 | HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF | EXXONMOBIL CHEM PATENTS INC (US) | 2013-06-05 | — | — | EP | claimed |
| US-7595420-B2 | Hydrogenation of benzene polycarboxylic acids or derivatives thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-09-29 | — | — | US | claimed |
| US-20060247461-A1 | Hydrogenation of benzene polycarboxylic acids or derivatives thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-11-02 | — | — | US | claimed |
| EP-1567470-A1 | HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004046078-A1 | HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-10017448-B2 | Process for hydrogenation of benzenepolycarboxylic acids and derivatives thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170291867-A1 | Improved Process for Hydrogenation of Benzenepolycarboxylic Acids and Derivatives Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2017-10-12 | — | — | US | disclosed |
| EP-1567470-B1 | HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF | EXXONMOBIL CHEM PATENTS INC (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8203017-B2 | Hydrogenation of benzene polycarboxylic acids or derivatives thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8143438-B2 | Hydrogenation processes | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110112322-A1 | Hydrogenation of Benzene Polycarboxylic Acids or Derivatives Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110082311-A1 | Hydrogenation Processes | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2011-04-07 | — | — | US | disclosed |
| EP-1412082-A1 | METHOD FOR HYDROGENATING ORGANIC COMPOUNDS BY MEANS OF RU/SIO2 CATALYSTS | BASF Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| EP-1314714-A2 | Method for hydrogenating benzene polycarboxylic acids or derivatives thereof by using a catalyst containing macropores | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1042273-B1 | METHOD FOR HYDROGENATING BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF BY USING A CATALYST CONTAINING MACROPORES | BASF AG (DE) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002100536-A1 | METHOD FOR HYDROGENATING ORGANIC COMPOUNDS BY MEANS OF RU/SIO2 CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | WO | disclosed |
| US-20020019559-A1 | Hydrogenation of benzenepolycarboxylic acids or derivatives thereof using a catalyst containing macropores | BRUNNER MELANIE (DE) | 2002-02-14 | — | — | US | disclosed |
| US-6284917-B1 | Method for hydrogenating benzene polycarboxylic acids or derivatives thereof by using a catalyst containing macropores | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-04 | — | — | US | disclosed |
| EP-1042273-A1 | METHOD FOR HYDROGENATING BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF BY USING A CATALYST CONTAINING MACROPORES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032427-A1 | METHOD FOR HYDROGENATING BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF BY USING A CATALYST CONTAINING MACROPORES | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082311-A1 | Hydrogenation Processes | HAO2, HVCN1, AOC3 | KDM4E 2731/4885CA12 1004/4885CA1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.